SUZANNE FUQUA to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications SUZANNE FUQUA has written about Xenograft Model Antitumor Assays.
Connection Strength
0.330
-
RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. Br J Cancer. 2021 01; 124(1):191-206.
Score: 0.143
-
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 2006 Jun 01; 66(11):5950-9.
Score: 0.052
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
Score: 0.047
-
Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
Score: 0.036
-
Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene. 2013 Jul 04; 32(27):3274-85.
Score: 0.020
-
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May; 121(1):1-11.
Score: 0.016
-
Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res. 2009 Jun 01; 69(11):4724-32.
Score: 0.016